Prominent Oncologist & Researcher Joins 4Dx Board

November 30, 2016

Australian technology start-up 4DX has attracted one of the biggest names in global oncology as its latest Board member.

Robert A. Figlin, MD, FACP, joins the 4Dx board on December 1st.  Dr Figlin is Deputy Director of the Integrated Oncology Service Line. He also serves as the Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles and is Director of the Hematology Oncology Division at the institute, where he is in charge of integrating research and clinical strategies across all the Cedars-Sinai campuses.

Since his arrival at Cedars- Sinai six years ago, he has established the Experimental Therapeutics Program and successfully recruited clinical research staff in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship, and cancer biology.

Dr Figlin says, “4Dx has developed some of the most promising and exciting technology I’ve ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth.”

Dr Figlin co-founded Agensys – an early stage biotechnology company focussed on developing novel therapies for cancer.  The company has since been sold to Astellas Pharmaceuticals as part of a nine-figure deal.

4Dx founder and chair, Andreas Fouras, says, “Bob Figlin brings unparalleled experience and expertise in cancer therapies to 4Dx, where enhanced cancer treatment is among our first priorities. “Bob brings a vast medical knowledge and adds enormous capacity to our board’s business decision making capacity.”

Lung cancer is the biggest killer of all cancers and the current standard treatments of chemotherapy and radiotherapy have devastating effects on the lungs. 4Dx technology is non-invasive and will positively impact the way medical professionals are able to diagnose, and treat their patients.

“4Dx is undergoing significant acceleration and is thrilled to have a clinician, researcher and entrepreneurial thinker in Bob Figlan join our team.”

“This revolutionary technology and the development of unique software to generate moving, ultra-high-resolution images of motion and airflow in lung tissue enables clinicians to view and measure abnormal lung function at the earliest stages of disease in a way that has not been possible before now.”

As well as their association with Cedars- Sinai, 4Dx has also created partnerships with other leading hospitals such as the Cleveland Clinic and the Children’s Hospital Los Angeles in the US, and The Alfred and Peter Mac in Australia.